The Federal Trade Commission is fining Dublin-based Cardinal Health nearly 27 million dollars for having a monopoly on drugs used to detect heart problems, and overcharging clinics and hospitals in 25 U.S. markets. In 2012, the company agreed to a two year suspension of it license to ship drugs from a Florida facility after the U.S. Drug Enforcement Administration said Cardinal improperly distributed prescription pain pills. In 2008, Cardinal settled with the DEA for 34 million dollars over allegations it failed to notify the agency about suspicious shipments of drugs to pharmacies that sold them online illegally.
FTC Fines Cardinal Health
Facebook Twitter LinkedIn Email